Exact Mass: 575.3584

Exact Mass Matches: 575.3584

Found 280 metabolites which its exact mass value is equals to given mass value 575.3584, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ergokryptine

alpha-Ergocryptine

C32H41N5O5 (575.3108)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

beta-Ergocryptine

5alpha(S)-sec-Butyl-12-hydroxy-2-isopropylergotaman-3,6,18-trione

C32H41N5O5 (575.3108)


alpha-Ergocryptine in which the isobutyl (2-methylpropyl) substituent is replaced by sec-butyl (1-methylpropyl). It is a natural ergot alkaloid. Note that ergocryptine discussed in the literature prior to 1967, when beta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine.

   

Fosteabine

SCHEMBL13524289

C27H50N3O8P (575.3335)


D000970 - Antineoplastic Agents

   

Mauritine A

(Z)-N-{1-[(8E,11E,13Z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-(dimethylamino)propimidic acid

C32H41N5O5 (575.3108)


Mauritine A is found in fruits. Mauritine A is an alkaloid from the stem bark of Zizyphus jujuba (Chinese date

   

LysoPC(22:2(13Z,16Z)/0:0)

(2-{[(2R)-3-[(13Z,16Z)-docosa-13,16-dienoyloxy]-2-hydroxypropyl phosphono]oxy}ethyl)trimethylazanium

C30H58NO7P (575.3951)


LysoPC(22:2(13Z,16Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(22:2(13Z,16Z)), in particular, consists of one chain of docosadienoic acid at the C-1 position. The docosadienoic acid moiety is derived from animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(22:2(13Z,16Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(22:2(13Z,16Z)), in particular, consists of one chain of docosadienoic acid at the C-1 position. The docosadienoic acid moiety is derived from animal fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   

N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide

N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide

C30H49N5O6 (575.3683)


   

Ergokryptine

N-[2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

C32H41N5O5 (575.3108)


   

Fosteabine

{[5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(octadecyloxy)phosphinic acid

C27H50N3O8P (575.3335)


D000970 - Antineoplastic Agents

   

PC(2:0/18:2(10E,12Z)+=O(9))

(2-{[(2R)-3-(acetyloxy)-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(2:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(18:2(10E,12Z)+=O(9)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(18:2(10E,12Z)+=O(9)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:2(10E,12Z)+=O(9)/2:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/18:2(9Z,11E)+=O(13))

(2-{[(2R)-3-(acetyloxy)-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(2:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(18:2(9Z,11E)+=O(13)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(18:2(9Z,11E)+=O(13)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:2(9Z,11E)+=O(13)/2:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/18:3(10,12,15)-OH(9))

(2-{[(2R)-3-(acetyloxy)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(2:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(18:3(10,12,15)-OH(9)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(18:3(10,12,15)-OH(9)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:3(10,12,15)-OH(9)/2:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(2:0/18:3(9,11,15)-OH(13))

(2-{[(2R)-3-(acetyloxy)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(2:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(18:3(9,11,15)-OH(13)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C28H50NO9P (575.3223)


PC(18:3(9,11,15)-OH(13)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:3(9,11,15)-OH(13)/2:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

Angeloylzygadenine

Angeloylzygadenine

C32H49NO8 (575.3458)


D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids

   

O-12-Methylergocornine

O-12-Methylergocornine

C32H41N5O5 (575.3108)


   

9(13)-Cyclodiscodermolide

9(13)-Cyclodiscodermolide

C33H53NO7 (575.3822)


   

Isorubijervosine

Isorubijervosine

C33H53NO7 (575.3822)


   
   
   

Yibeinoside A

Yibeinoside A

C33H53NO7 (575.3822)


   
   

5-epi-beta-Ergocryptine

5-epi-beta-Ergocryptine

C32H41N5O5 (575.3108)


   

C6 NBD Ceramide

C6 NBD Ceramide

C30H49N5O6 (575.3683)


   
   

leptinidine 3-O-beta-D-glucopyranoside

leptinidine 3-O-beta-D-glucopyranoside

C33H53NO7 (575.3822)


   

(25R)-22,26-epimino-3beta-hydroxy-5alpha-cholest-22(N)-en-6-one 3-O-beta-D-glucopyranoside

(25R)-22,26-epimino-3beta-hydroxy-5alpha-cholest-22(N)-en-6-one 3-O-beta-D-glucopyranoside

C33H53NO7 (575.3822)


   

Solasodine glucoside

Solasodine glucoside

C33H53NO7 (575.3822)


   

(3beta,16beta,17alpha,20S)-16-hydroxy-17-methyl-20-[(2S,5S)-5-methylpiperidin-2-yl]-18-norpregna-5,12-dien-3-yl beta-D-glucopyranoside|veralkamine 3-(beta-D-glucopyranoside)

(3beta,16beta,17alpha,20S)-16-hydroxy-17-methyl-20-[(2S,5S)-5-methylpiperidin-2-yl]-18-norpregna-5,12-dien-3-yl beta-D-glucopyranoside|veralkamine 3-(beta-D-glucopyranoside)

C33H53NO7 (575.3822)


   

2beta,16alpha,20beta,25-tetrahydroxy-24-acetylaminocucurbita-5-en-3,11,22-trione|endecaphyllacin C

2beta,16alpha,20beta,25-tetrahydroxy-24-acetylaminocucurbita-5-en-3,11,22-trione|endecaphyllacin C

C32H49NO8 (575.3458)


   
   

viridiofungin B

viridiofungin B

C31H45NO9 (575.3094)


   

Lys Thr Glu Lys Ala

Lys Thr Glu Lys Ala

C24H45N7O9 (575.3279)


   

Tyr Leu Pro Ala Val

Tyr Leu Pro Ala Val

C29H45N5O7 (575.3319)


   

Leu Val Leu Gly Phe

Leu Val Leu Gly Phe

C30H49N5O6 (575.3683)


   

Leu Val Phe Ala Ile

Leu Val Phe Ala Ile

C30H49N5O6 (575.3683)


   

Gly Phe Leu Leu Val

Gly Phe Leu Leu Val

C30H49N5O6 (575.3683)


   

alpha-Ergocryptine

alpha-Ergocryptine

C32H41N5O5 (575.3108)


Ergotaman bearing hydroxy, isopropyl, and 2-methylpropyl groups at the 12, 2 and 5 positions, respectively, and oxo groups at positions 3, 6, and 18. It is a natural ergot alkaloid. Ergocryptine discussed in the literature prior to 1967, when beta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine. D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists relative retention time with respect to 9-anthracene Carboxylic Acid is 1.085 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.083 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.081 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.080

   

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

NCGC00380641-01!5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

C25H45N5O10 (575.3166)


   

Angeloylzygadenin

Angeloylzygadenin

C32H49NO8 (575.3458)


   

ergocryptine

12-hydroxy-2-(1-methylethyl)-5alpha-(2-methylpropyl)ergotaman-3,6,18-trione

C32H41N5O5 (575.3108)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists CONFIDENCE Claviceps purpurea sclerotia

   

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

C25H45N5O10 (575.3166)


   

Ergocryptinine

Ergocryptinine

C32H41N5O5 (575.3108)


CONFIDENCE Reference Standard (Level 1)

   

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid_major

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid_major

C25H45N5O10 (575.3166)


   

Lys Arg Ser Trp

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Lys Arg Trp Ser

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Lys Ser Arg Trp

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]pentanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Lys Ser Trp Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]pentanoic acid

C26H41N9O6 (575.318)


   

Lys Trp Arg Ser

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]pentanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Lys Trp Ser Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]pentanoic acid

C26H41N9O6 (575.318)


   

Arg Lys Ser Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Arg Lys Trp Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Arg Ser Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Arg Ser Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C26H41N9O6 (575.318)


   

Arg Trp Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Arg Trp Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]hexanoic acid

C26H41N9O6 (575.318)


   

Ser Lys Arg Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Ser Lys Trp Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C26H41N9O6 (575.318)


   

Ser Arg Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N9O6 (575.318)


   

Ser Arg Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C26H41N9O6 (575.318)


   

Ser Trp Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanoic acid

C26H41N9O6 (575.318)


   

Ser Trp Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanoic acid

C26H41N9O6 (575.318)


   

Trp Lys Arg Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Trp Lys Ser Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C26H41N9O6 (575.318)


   

Trp Arg Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanamido]-3-hydroxypropanoic acid

C26H41N9O6 (575.318)


   

Trp Arg Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]hexanoic acid

C26H41N9O6 (575.318)


   

Trp Ser Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]hexanamido]-5-carbamimidamidopentanoic acid

C26H41N9O6 (575.318)


   

Trp Ser Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]hexanoic acid

C26H41N9O6 (575.318)


   

KTEKA

Lys Thr Glu Lys Ala

C24H45N7O9 (575.3279)


   

LPC(22:2)

1-Docosadienoyl-glycero-3-phosphocholine

C30H58NO7P (575.3951)


   

C-6 NBD Ceramide

N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine

C30H49N5O6 (575.3683)


   

PC(22:2(13Z,16Z)/0:0)

1-(13Z,16Z-docosadienoyl)-glycero-3-phosphocholine

C30H58NO7P (575.3951)


   

Mauritine A

N-(1-{10-benzyl-8,11-dioxo-2-oxa-6,9,12-triazatricyclo[13.2.2.0^{3,7}]nonadeca-1(17),13,15,18-tetraen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(dimethylamino)propanamide

C32H41N5O5 (575.3108)


A natural product found in Ziziphus apetala.

   

3,14,25-Trihydroxy-2,10,13,21,24-pentaoxo-3,9,14,20,25-pentaazatriacontan-30-oic acid

3,14,25-Trihydroxy-2,10,13,21,24-pentaoxo-3,9,14,20,25-pentaazatriacontan-30-oic acid

C25H45N5O10 (575.3166)


   

ibha#30

3R-hydroxy-16R-(3R-hydroxy-5R-O-(1H-indol-3-ylcarbonyl)-6S-methyl-(2H)-tetrahydropyran-2-yloxy)-heptadecanoic acid

C32H49NO8 (575.3458)


An (omega-1)-hydroxy fatty acid ascaroside that is bhas#30 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.

   

LPC 22:2

1-(13Z,16Z-docosadienoyl)-glycero-3-phosphocholine

C30H58NO7P (575.3951)


   

LPC 20:4;O2

2-(12S-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine

C28H50NO9P (575.3223)


   

(3beta)-3-Hydroxy-2-(hydroxyimino)olean-12-en-28-oic acid phenylmethyl ester

(3beta)-3-Hydroxy-2-(hydroxyimino)olean-12-en-28-oic acid phenylmethyl ester

C37H53NO4 (575.3974)


   

2-N-HEXADECANOYLAMINO-4-NITROPHENYLPHOSPHORYLCHOLINE

2-N-HEXADECANOYLAMINO-4-NITROPHENYLPHOSPHORYLCHOLINE

C27H50N3O8P (575.3335)


   

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one

6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one

C31H45N9O2 (575.3696)


   

boc-l-melys(z)-oh

boc-l-melys(z)-oh

C32H53N3O6 (575.3934)


   

NBD-Ceramide

NBD-Ceramide

C30H49N5O6 (575.3683)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes

   

(3R,16R)-16-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}-3-hydroxymargaric acid

(3R,16R)-16-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}-3-hydroxymargaric acid

C32H49NO8 (575.3458)


   

Solasodine 3-glucoside

Solasodine 3-glucoside

C33H53NO7 (575.3822)


   

(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-[(1S,2S,4S,5R,6R,7S,8R,9R,12S,13R,16S)-5,7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-piperidine]-16-yl]oxyoxane-3,4,5-triol

(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-[(1S,2S,4S,5R,6R,7S,8R,9R,12S,13R,16S)-5,7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-piperidine]-16-yl]oxyoxane-3,4,5-triol

C33H53NO7 (575.3822)


   

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(1S,2S,4S,5R,6R,7S,8R,9R,12S,13R,16S)-5,7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-piperidine]-16-yl]oxyoxane-3,4,5-triol

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(1S,2S,4S,5R,6R,7S,8R,9R,12S,13R,16S)-5,7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-piperidine]-16-yl]oxyoxane-3,4,5-triol

C33H53NO7 (575.3822)


   

Hexanamide, N-(2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-6-((7-nitro-4-benzofurazanyl)amino)-

Hexanamide, N-(2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-6-((7-nitro-4-benzofurazanyl)amino)-

C30H49N5O6 (575.3683)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes

   

PC(2:0/18:2(10E,12Z)+=O(9))

PC(2:0/18:2(10E,12Z)+=O(9))

C28H50NO9P (575.3223)


   

PC(18:2(10E,12Z)+=O(9)/2:0)

PC(18:2(10E,12Z)+=O(9)/2:0)

C28H50NO9P (575.3223)


   

PC(2:0/18:2(9Z,11E)+=O(13))

PC(2:0/18:2(9Z,11E)+=O(13))

C28H50NO9P (575.3223)


   

PC(18:2(9Z,11E)+=O(13)/2:0)

PC(18:2(9Z,11E)+=O(13)/2:0)

C28H50NO9P (575.3223)


   

[(2R)-3-acetyloxy-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-3-acetyloxy-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)


   

[(2R)-2-acetyloxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-acetyloxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)


   

[(2R)-3-acetyloxy-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-3-acetyloxy-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)


   

[(2R)-2-acetyloxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-acetyloxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)


   

Epimauritine A

Epimauritine A

C32H41N5O5 (575.3108)


A natural product found in Ziziphus apetala.

   

Bromocriptine Impurity B

Bromocriptine Impurity B

C32H41N5O5 (575.3108)


   

5alpha-(Butan-2-yl)-12-hydroxy-3,6,18-trioxo-2-(propan-2-yl)ergotaman

5alpha-(Butan-2-yl)-12-hydroxy-3,6,18-trioxo-2-(propan-2-yl)ergotaman

C32H41N5O5 (575.3108)


   

N-(2-hydroxyhexanoyl)-beta-D-galactosylsphingosine

N-(2-hydroxyhexanoyl)-beta-D-galactosylsphingosine

C30H57NO9 (575.4033)


A N-(2-hydroxyacyl)-beta-D-galactosylsphingosine in which the ceramide N-acyl group is specified as 2-hydroxyhexanoyl.

   

calcidiol 25-O-(beta-D-glucuronide)

calcidiol 25-O-(beta-D-glucuronide)

C33H51O8- (575.3584)


   

(1S,3Z)-3-[(2E)-2-{(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyloctahydro-4H-inden-4-ylidene}ethylidene]-4-methylidenecyclohexyl beta-D-glucopyranosiduronate

(1S,3Z)-3-[(2E)-2-{(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyloctahydro-4H-inden-4-ylidene}ethylidene]-4-methylidenecyclohexyl beta-D-glucopyranosiduronate

C33H51O8- (575.3584)


   

1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)


   

1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)


   

1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)


   

1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)


   

1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)


   

[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

2-amino-3-[[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C28H50NO9P (575.3223)


   

Lnape 16:2/N-8:0

Lnape 16:2/N-8:0

C29H54NO8P (575.3587)


   

Lnape 20:2/N-4:0

Lnape 20:2/N-4:0

C29H54NO8P (575.3587)


   

Lnape 21:2/N-3:0

Lnape 21:2/N-3:0

C29H54NO8P (575.3587)


   

Lnape 8:0/N-16:2

Lnape 8:0/N-16:2

C29H54NO8P (575.3587)


   

Lnape 17:2/N-7:0

Lnape 17:2/N-7:0

C29H54NO8P (575.3587)


   

Lnape 5:0/N-19:2

Lnape 5:0/N-19:2

C29H54NO8P (575.3587)


   

Lnape 22:2/N-2:0

Lnape 22:2/N-2:0

C29H54NO8P (575.3587)


   

Lnape 4:0/N-20:2

Lnape 4:0/N-20:2

C29H54NO8P (575.3587)


   

Lnape 18:2/N-6:0

Lnape 18:2/N-6:0

C29H54NO8P (575.3587)


   

Lnape 2:0/N-22:2

Lnape 2:0/N-22:2

C29H54NO8P (575.3587)


   

Lnape 19:2/N-5:0

Lnape 19:2/N-5:0

C29H54NO8P (575.3587)


   

Lnape 3:0/N-21:2

Lnape 3:0/N-21:2

C29H54NO8P (575.3587)


   

Lnape 6:0/N-18:2

Lnape 6:0/N-18:2

C29H54NO8P (575.3587)


   

Lnape 7:0/N-17:2

Lnape 7:0/N-17:2

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] butanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] butanoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] octanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] octanoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] propanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] propanoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] pentanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] pentanoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] hexanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] hexanoate

C30H58NO7P (575.3951)


   

[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

[2-acetyloxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-acetyloxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

[3-[(9Z,12Z)-nonadeca-9,12-dienoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-[(9Z,12Z)-nonadeca-9,12-dienoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

(E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid

(E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid

C33H53NO5S (575.3644)


   

(4E,8E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]trideca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]trideca-4,8-diene-1-sulfonic acid

C33H53NO5S (575.3644)


   

(4E,8E,12E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyheptadeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyheptadeca-4,8,12-triene-1-sulfonic acid

C33H53NO5S (575.3644)


   

(4E,8E,12E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]pentadeca-4,8,12-triene-1-sulfonic acid

(4E,8E,12E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]pentadeca-4,8,12-triene-1-sulfonic acid

C33H53NO5S (575.3644)


   

(4E,8E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]pentadeca-4,8-diene-1-sulfonic acid

(4E,8E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]pentadeca-4,8-diene-1-sulfonic acid

C33H53NO5S (575.3644)


   

[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-hexanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-hexanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

4-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C33H53NO7 (575.3822)


   

4-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-propanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

4-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-propanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate

C33H53NO7 (575.3822)


   

[2-butanoyloxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-butanoyloxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] heptanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] heptanoate

C30H58NO7P (575.3951)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] nonanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] nonanoate

C30H58NO7P (575.3951)


   

[3-acetyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-acetyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C29H54NO8P (575.3587)


   

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C29H54NO8P (575.3587)


   

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C29H54NO8P (575.3587)


   

[3-butanoyloxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-butanoyloxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C29H54NO8P (575.3587)


   

[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C29H54NO8P (575.3587)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C29H54NO8P (575.3587)


   
   

LysoPC(22:2(13Z,16Z))

LysoPC(22:2(13Z,16Z))

C30H58NO7P (575.3951)


   

calcidiol 3-O-(beta-D-glucuronate)

calcidiol 3-O-(beta-D-glucuronate)

C33H51O8 (575.3584)


A steroid glucuronide anion that is the conjugate base of calcidiol 3-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

lysophosphatidylcholine 22:2

lysophosphatidylcholine 22:2

C30H58NO7P (575.3951)


A lysophosphatidylcholine in which the remaining acyl group contains 22 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.

   
   

N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine

N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine

C30H49N5O6 (575.3683)


An N-acylsphingosine that is sphingosine with the amino nitrogen converted into a 6-{[N-(7-nitrobenzo-2,1,3-oxadiazol-4-yl)amino]}hexananamido group.

   

calcidiol 25-O-(beta-D-glucuronate)

calcidiol 25-O-(beta-D-glucuronate)

C33H51O8 (575.3584)


A steroid glucuronide anion that is the conjugate base of calcidiol 25-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

MePC(21:2)

MePC(10:0(1)_11:2)

C30H58NO7P (575.3951)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

PC(21:2)

PC(10:0_11:2)

C29H54NO8P (575.3587)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

MePC(20:2)

MePC(6:0_14:2)

C29H54NO8P (575.3587)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

dMePE(22:2)

dMePE(4:0_18:2)

C29H54NO8P (575.3587)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   
   
   
   

PC P-16:1/5:1;O

PC P-16:1/5:1;O

C29H54NO8P (575.3587)


   
   

PC P-18:0/4:1 or PC O-18:1/4:1

PC P-18:0/4:1 or PC O-18:1/4:1

C30H58NO7P (575.3951)


   
   

PC P-18:1/4:0 or PC O-18:2/4:0

PC P-18:1/4:0 or PC O-18:2/4:0

C30H58NO7P (575.3951)


   
   

PC P-20:1/2:0 or PC O-20:2/2:0

PC P-20:1/2:0 or PC O-20:2/2:0

C30H58NO7P (575.3951)


   
   

PC P-22:1 or PC O-22:2

PC P-22:1 or PC O-22:2

C30H58NO7P (575.3951)


   
   
   
   
   
   
   
   

PE O-16:0/8:3;O

PE O-16:0/8:3;O

C29H54NO8P (575.3587)


   
   
   

PE P-16:0/7:3;O2

PE P-16:0/7:3;O2

C28H50NO9P (575.3223)


   

PE P-16:1/7:2;O2

PE P-16:1/7:2;O2

C28H50NO9P (575.3223)


   

PE P-16:1/8:1;O

PE P-16:1/8:1;O

C29H54NO8P (575.3587)


   

PE P-18:0/6:2;O

PE P-18:0/6:2;O

C29H54NO8P (575.3587)


   

PE P-18:1/5:2;O2

PE P-18:1/5:2;O2

C28H50NO9P (575.3223)


   

PE P-20:1/4:1;O

PE P-20:1/4:1;O

C29H54NO8P (575.3587)


   
   
   
   
   
   
   
   
   
   
   

PS P-18:1/4:1 or PS O-18:2/4:1

PS P-18:1/4:1 or PS O-18:2/4:1

C28H50NO9P (575.3223)


   
   

PS P-22:2 or PS O-22:3

PS P-22:2 or PS O-22:3

C28H50NO9P (575.3223)


   

CerP 14:2;O2/16:0;O

CerP 14:2;O2/16:0;O

C30H58NO7P (575.3951)


   

CerP 15:2;O2/15:0;O

CerP 15:2;O2/15:0;O

C30H58NO7P (575.3951)


   

CerP 16:2;O2/14:0;O

CerP 16:2;O2/14:0;O

C30H58NO7P (575.3951)


   

CerP 17:2;O2/13:0;O

CerP 17:2;O2/13:0;O

C30H58NO7P (575.3951)


   

CerP 18:2;O2/12:0;O

CerP 18:2;O2/12:0;O

C30H58NO7P (575.3951)


   

CerP 19:2;O2/11:0;O

CerP 19:2;O2/11:0;O

C30H58NO7P (575.3951)


   

CerP 20:2;O2/10:0;O

CerP 20:2;O2/10:0;O

C30H58NO7P (575.3951)


   
   

GalCer 14:1;O2/10:0;O

GalCer 14:1;O2/10:0;O

C30H57NO9 (575.4033)


   

GalCer 24:1;O2;O

GalCer 24:1;O2;O

C30H57NO9 (575.4033)


   

GlcCer 14:1;O2/10:0;O

GlcCer 14:1;O2/10:0;O

C30H57NO9 (575.4033)


   

GlcCer 24:1;O2;O

GlcCer 24:1;O2;O

C30H57NO9 (575.4033)


   

HexCer 14:1;O2/10:0;2OH

HexCer 14:1;O2/10:0;2OH

C30H57NO9 (575.4033)


   

HexCer 14:1;O2/10:0;3OH

HexCer 14:1;O2/10:0;3OH

C30H57NO9 (575.4033)


   

HexCer 14:1;O2/10:0;O

HexCer 14:1;O2/10:0;O

C30H57NO9 (575.4033)


   

HexCer 24:1;O2;O

HexCer 24:1;O2;O

C30H57NO9 (575.4033)


   

ST 29:5;O7;Gly

ST 29:5;O7;Gly

C31H45NO9 (575.3094)


   

ST 23:4;O4;HexNAc

ST 23:4;O4;HexNAc

C31H45NO9 (575.3094)


   

ST 24:3;O3;HexNAc

ST 24:3;O3;HexNAc

C32H49NO8 (575.3458)


   

ST 25:2;O2;HexNAc

ST 25:2;O2;HexNAc

C33H53NO7 (575.3822)


   
   
   

6,10,23-trimethyl-21-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

6,10,23-trimethyl-21-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

C33H53NO7 (575.3822)


   

(4r,7r)-n-[(1s,2s,4r)-2-hydroxy-4-isopropyl-5,8-dioxo-7-(sec-butyl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r)-2-hydroxy-4-isopropyl-5,8-dioxo-7-(sec-butyl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(4s,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4s,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl 2-methylbut-2-enoate

10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl 2-methylbut-2-enoate

C32H49NO8 (575.3458)


   

(2s,3r)-2-({[(3s,6s,9r)-6-[(2r)-butan-2-yl]-2,5,8-trihydroxy-3-[2-(4-hydroxyphenyl)ethyl]-1,4,7-triazacyclotrideca-1,4,7-trien-9-yl]-c-hydroxycarbonimidoyl}amino)-3-methylpentanoic acid

(2s,3r)-2-({[(3s,6s,9r)-6-[(2r)-butan-2-yl]-2,5,8-trihydroxy-3-[2-(4-hydroxyphenyl)ethyl]-1,4,7-triazacyclotrideca-1,4,7-trien-9-yl]-c-hydroxycarbonimidoyl}amino)-3-methylpentanoic acid

C29H45N5O7 (575.3319)


   

n-[2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

n-[2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

2-(hydroxymethyl)-6-{[(7s,10r,14r,15r,16s,17r,20s,23s)-14-(hydroxymethyl)-10,16,20-trimethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-yl]oxy}oxane-3,4,5-triol

2-(hydroxymethyl)-6-{[(7s,10r,14r,15r,16s,17r,20s,23s)-14-(hydroxymethyl)-10,16,20-trimethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-yl]oxy}oxane-3,4,5-triol

C33H53NO7 (575.3822)


   

α-ergokryptinine

NA

C32H41N5O5 (575.3108)


{"Ingredient_id": "HBIN015506","Ingredient_name": "\u03b1-ergokryptinine","Alias": "NA","Ingredient_formula": "C32H41N5O5","Ingredient_Smile": "CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=CNC7=CC=CC(=C67)C5=C4)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7237","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1r,3as,3bs,5as,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-5-one

(1r,3as,3bs,5as,7s,9ar,9bs,11as)-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-5-one

C33H53NO7 (575.3822)


   

(4s,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4s,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(3s,4r,5s,6s)-4-hydroxy-6-[(2e)-3-[(1s,2r,3r,4s,5r)-3-hydroxy-5-[(2e,4s,5r,6r,7s,8s,9z)-5-hydroxy-7-(c-hydroxycarbonimidoyloxy)-4,6,8-trimethyldodeca-2,9,11-trien-2-yl]-2,4-dimethylcyclopentyl]prop-2-en-1-yl]-3,5-dimethyloxan-2-one

(3s,4r,5s,6s)-4-hydroxy-6-[(2e)-3-[(1s,2r,3r,4s,5r)-3-hydroxy-5-[(2e,4s,5r,6r,7s,8s,9z)-5-hydroxy-7-(c-hydroxycarbonimidoyloxy)-4,6,8-trimethyldodeca-2,9,11-trien-2-yl]-2,4-dimethylcyclopentyl]prop-2-en-1-yl]-3,5-dimethyloxan-2-one

C33H53NO7 (575.3822)


   

4-(1,3-dihydroxypentyl)-2,4,18,20-tetramethyl-5,27-dioxa-12-azatricyclo[22.2.1.0⁷,¹²]heptacosa-14,20-diene-6,13,19-trione

4-(1,3-dihydroxypentyl)-2,4,18,20-tetramethyl-5,27-dioxa-12-azatricyclo[22.2.1.0⁷,¹²]heptacosa-14,20-diene-6,13,19-trione

C33H53NO7 (575.3822)


   

2-[(2e)-1-[(1-carboxy-2-phenylethyl)-c-hydroxycarbonimidoyl]-10-oxoheptadec-2-en-1-yl]-2-hydroxybutanedioic acid

2-[(2e)-1-[(1-carboxy-2-phenylethyl)-c-hydroxycarbonimidoyl]-10-oxoheptadec-2-en-1-yl]-2-hydroxybutanedioic acid

C31H45NO9 (575.3094)


   

(4r,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

2-({2-hydroxy-9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

2-({2-hydroxy-9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C33H53NO7 (575.3822)


   

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1s,2r,7s,10r,11s,14s,15r,16r,17r,20r,23s)-14-(hydroxymethyl)-10,16,20-trimethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-yl]oxy}oxane-3,4,5-triol

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1s,2r,7s,10r,11s,14s,15r,16r,17r,20r,23s)-14-(hydroxymethyl)-10,16,20-trimethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-7-yl]oxy}oxane-3,4,5-triol

C33H53NO7 (575.3822)


   

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-(dimethylamino)propanimidic acid

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)


   

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2r)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2r)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

C32H49NO8 (575.3458)


   

(2r,3r,4s,5s,6r)-2-{[(1r,2r,3as,3bs,7s,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1r,2r,3as,3bs,7s,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5s)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C33H53NO7 (575.3822)


   

(2s)-n-[(2s)-1-[(3s,7s,10s)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

(2s)-n-[(2s)-1-[(3s,7s,10s)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)


   

n-{4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl}-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

n-{4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl}-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-5-one

9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-5-one

C33H53NO7 (575.3822)


   

6,10,23-trimethyl-20-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

6,10,23-trimethyl-20-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

C33H53NO7 (575.3822)


   

3-methyl-2-[({2,5,8-trihydroxy-3-[2-(4-hydroxyphenyl)ethyl]-6-(sec-butyl)-1,4,7-triazacyclotrideca-1,4,7-trien-9-yl}-c-hydroxycarbonimidoyl)amino]pentanoic acid

3-methyl-2-[({2,5,8-trihydroxy-3-[2-(4-hydroxyphenyl)ethyl]-6-(sec-butyl)-1,4,7-triazacyclotrideca-1,4,7-trien-9-yl}-c-hydroxycarbonimidoyl)amino]pentanoic acid

C29H45N5O7 (575.3319)


   

(1r,2s,6s,9s,10r,11r,14s,15s,18s,20s,23r,24s)-6,10,23-trimethyl-20-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

(1r,2s,6s,9s,10r,11r,14s,15s,18s,20s,23r,24s)-6,10,23-trimethyl-20-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-17-one

C33H53NO7 (575.3822)


   

n-(1-{10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(dimethylamino)propanimidic acid

n-(1-{10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)


   

(4r,7r)-n-[(1s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(2r,5s,8s,11s)-3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

(2r,5s,8s,11s)-3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

C30H45N3O8 (575.3206)


   

(7s,14z,20z)-4-(1,3-dihydroxypentyl)-2,4,18,20-tetramethyl-5,27-dioxa-12-azatricyclo[22.2.1.0⁷,¹²]heptacosa-14,20-diene-6,13,19-trione

(7s,14z,20z)-4-(1,3-dihydroxypentyl)-2,4,18,20-tetramethyl-5,27-dioxa-12-azatricyclo[22.2.1.0⁷,¹²]heptacosa-14,20-diene-6,13,19-trione

C33H53NO7 (575.3822)


   

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)


   

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23r,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23r,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

C32H49NO8 (575.3458)


   

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1s,4s,5'r,6r,7s,9s,12s,13r,16s)-5',7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-eneoxy]oxane-3,4,5-triol

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1s,4s,5'r,6r,7s,9s,12s,13r,16s)-5',7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-eneoxy]oxane-3,4,5-triol

C33H53NO7 (575.3822)


   

3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

C30H45N3O8 (575.3206)


   

6,10,23-trimethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-20-one

6,10,23-trimethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacosan-20-one

C33H53NO7 (575.3822)


   

(4r,7r)-n-[(1s,2s,4r,7r)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r,7r)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(7r)-n-[(1s,2s,4r,7s)-7-butyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(7r)-n-[(1s,2s,4r,7s)-7-butyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)


   

(1s,2s,6s,9s,10s,11r,12r,13s,15s,19s,22s,23s)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

(1s,2s,6s,9s,10s,11r,12r,13s,15s,19s,22s,23s)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl (2z)-2-methylbut-2-enoate

C32H49NO8 (575.3458)


   

(4r,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4r,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)